# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Numberk191638  
B ApplicantMedTest Dx

# C Proprietary and Established Names

Pointe scientific cocaine metabolite enzyme immunoassay

# D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DIO</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.3250 -Cocaine And CocaineMetabolite TestSystem</td><td rowspan=1 colspan=1>TX - ClinicalToxicology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New Device   
B Measurand: Benzoylecgonine   
C Type of Test: Immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s):

See Indications for Use below.

# B Indication(s) for Use:

The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay is intended for the qualitative determination of benzoylecgonine (a cocaine metabolite) in human urine at a cutoff value of 150 $\mathrm { n g / m L }$ . Rx only.

This assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or Liquid Chromatograph/Mass Spectrometry (GC/MS or LC/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

D Special Instrument Requirements:

BS-480 Chemistry Analyzer BA-800 Chemistry Analyzer

# IV Device/System Characteristics:

# A Device Description:

The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay consists of ready-to-use liquid reagents:

Reagent 1 contains a mouse monoclonal anti-benzoylecgonine antibody, glucose-6- phosphate (G6P) nicotinamide adenine dinucleotide (NAD), stabilizers and sodium azide $( 0 . 0 9 \% )$ as a preservative. Reagent 2 contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with benzoylecgonine in buffer with sodium azide $( 0 . 0 9 \% )$ as a preservative.

The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay has a cutoff of $1 5 0 ~ \mathrm { n g / m L }$ benzoylecgonine.

B Principle of Operation:

The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity. In the absence of drug in the sample, benzoylecgonine-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. On the other hand, when drug is present in the sample, antibody binds to the free drug; the unbound benzoylecgoninelabeled G6PDH then exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at a $3 4 0 \mathrm { n m }$ primary wavelength.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Cocaine Metabolite Enzyme Immunoassay

B Predicate 510(k) Number(s): k113139

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">k191638</td><td colspan="1" rowspan="1">k113139</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Pointe Scientific CocaineMetabolite EnzymeImmunoassay</td><td colspan="1" rowspan="1">Cocaine MetaboliteEnzyme Immunoassay</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">To be used for thedetermination ofbenzoylecgonine in humanurine.This assay provides only apreliminary analytical testresult. A more specificalternative chemical methodmust be used in order toobtain a confirmed analyticalresult. Gas or LiquidChromatograph/MassSpectrometry (GC/MS orLC/MS) is the preferredconfirmatory method.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Contents</td><td colspan="1" rowspan="1">The assay consists of ready-to-use liquid reagents.Reagent 1 contains a mouse</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">monoclonal anti-benzoylecgonine antibody,glucose-6-phosphate (G6P)nicotinamideadenine dinucleotide (NAD),stabilizers and sodium azide(0.09%) as a preservative.Reagent 2 contains glucose-6-phosphate dehydrogenase(G6PDH) labeled withbenzoylecgonine in bufferwith sodium azide (0.09%) asa preservative</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Cutoff</td><td colspan="1" rowspan="1">150 ng/mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Urine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">2 levels (112.5 ng/mL, 187.5ng/mL)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8Â°C until expiration date</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">2 Levels (0 ng/mL, 150ng/mL)</td><td colspan="1" rowspan="1">5 Levels (0, 75, 150,300, 1000 ng/mL)</td></tr></table>

# VI Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Reproducibility:

Precision was determined by spiking benzoylecgonine into drug free urine at various concentrations (zero, $- 7 5 \%$ , $- 5 0 \%$ , $- 2 5 \%$ , at the cutoff, $12 5 \%$ , $1 5 0 \%$ , $1 7 5 \%$ and $20 \%$ of the cutoff). Concentrations were confirmed by LC/MS. Testing for both the with-in run and between-run studies were performed by testing each sample in 2 replicates, with two runs per day, for 20 days, on both the BS-480 Chemistry Analyzer and the BS-800M Chemistry Analyzer. The qualitative results are presented below as Positive/Negative.

BS-480 Chemistry Analyzer:   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Within Run</td><td colspan="2" rowspan="1">Between Run</td></tr><tr><td colspan="1" rowspan="1">Sampleconcentration(ng/mL)</td><td colspan="1" rowspan="1">No.Observations</td><td colspan="1" rowspan="1"># Neg/#Pos</td><td colspan="1" rowspan="1">No.Observations</td><td colspan="1" rowspan="1"># Neg/#Pos</td></tr><tr><td colspan="1" rowspan="1">0 (negative)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20/0</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80/0</td></tr><tr><td colspan="1" rowspan="1">37.5 (-75% c/o)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20/0</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80/0</td></tr><tr><td colspan="1" rowspan="1">75 (-50% c/o)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20/0</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80/0</td></tr><tr><td colspan="1" rowspan="1">112.5 (-25% c/o)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20/0</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80/0</td></tr><tr><td colspan="1" rowspan="1">150 (cutoff)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">19/1</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">68/12</td></tr><tr><td colspan="1" rowspan="1">187.5 (+25% c/o)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">0/80</td></tr><tr><td colspan="1" rowspan="1">225 (+50% c/o)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">0/80</td></tr><tr><td colspan="1" rowspan="1">262.5 (+75% c/o)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">0/80</td></tr><tr><td colspan="1" rowspan="1">300 (+100% c/o)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">0/80</td></tr></table>

BA-800M Chemistry Analyzer:   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td></tr><tr><td rowspan=1 colspan=1>Sampleconcentration(ng/mL)</td><td rowspan=1 colspan=1>No.Observations</td><td rowspan=1 colspan=1># Neg/#Pos</td><td rowspan=1 colspan=1>No.Observations</td><td rowspan=1 colspan=1># Neg/#Pos</td></tr><tr><td rowspan=1 colspan=1>0 (negative)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20/0</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>37.5 (-75% c/o)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20/0</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>75 (-50% c/o)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20/0</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>112.5 (-25% c/o)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20/0</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80/0</td></tr><tr><td rowspan=1 colspan=1>150 (cutoff)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>7/13</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>41/39</td></tr><tr><td rowspan=1 colspan=1>187.5 (+25% c/o)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0/20</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>225 (+50% c/o)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0/20</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>262.5 (+75% c/o)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0/20</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr><tr><td rowspan=1 colspan=1>300 (+100% c/o)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0/20</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0/80</td></tr></table>

2. Linearity:

Not applicable.

# 3. Analytical Specificity/Interference:

The following endogenous compounds were added into drug-free urine, urine sample spiked with benzoylecgonine to $7 5 \%$ of cutoff value and urine spiked with benzoylecgonine to $12 5 \%$ of cutoff value. The substances listed in the table below were determined not to interfere at the concentration shown.

Results were identical for both the BS-480 Chemistry Analyzer and the BS-800M Chemistry Analyzer.

<table><tr><td rowspan="2">Interfering Substances</td><td rowspan="2">Spiked [] (mg/dL)</td><td colspan="3">Qualitative Result</td></tr><tr><td>0 ng/mL (Pos/Neg)</td><td>112.5 ng/mL Control (Pos/Neg)</td><td>187.5 ng/mL Control (Pos/Neg)</td></tr><tr><td>Acetaminophen</td><td>10</td><td>Neg</td><td>Neg</td><td>Pos</td></tr><tr><td colspan="1" rowspan="1">Acetone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid</td><td colspan="1" rowspan="1">400</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Aspirin</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ethanol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Galactose</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">r-Globulin</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Glucose</td><td colspan="1" rowspan="1">1500</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Human Serum Albumin</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Oxalic Acid</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Riboflavin</td><td colspan="1" rowspan="1">7.5</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Sodium Chloride</td><td colspan="1" rowspan="1">3000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">2000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr></table>

To test for possible positive and/or negative interference from $\mathsf { p H }$ , urine samples having pH from 3, 4, 5, 6, 7, 8, 9, 10 and 11 were used. Each of these samples were divided into two aliquots for each drug and spiked with benzoylecgonine to $7 5 \%$ of the cutoff and $12 5 \%$ of the cutoff. No positive or negative interference due to $\mathsf { p H }$ was observed on either the BS-480 Chemistry Analyzer or the BS-800M Chemistry Analyzer.

To test for possible positive and/or negative interference from specific gravity, urine samples having specific gravity ranging from $1 . 0 0 9 \ : \mathrm { g / m L }$ to $1 . 0 3 1 \ \mathrm { g / m L }$ were used. Each of these samples were divided into three aliquots and two were spiked with benzoylecgonine to $7 5 \%$ of the cutoff and $12 5 \%$ of the cutoff, the third was not spiked. No positive or negative interference due to specific gravity was observed on either the BS-480 Chemistry Analyzer or the BS-800M Chemistry Analyzer.

# Cross Reactivity

Cross-reactivity was established by spiking various concentrations of structurally related and unrelated compounds into drug-free urine.

The following tables summarize approximate the quantity of each compound that is equivalent in assay reactivity to the $1 5 0 ~ \mathrm { { n g / m L } }$ benzoylecgonine cutoff. Results are expressed as a minimum concentration of metabolite or compound required to produce a response approximately equivalent to the cutoff concentration of the assay or the maximal concentration of the compound tested that gave a response with cross-reactivity below the cutoff calibrator. The percent cross-reactivity of those compounds are presented below.

Structurally Related Cocaine Compound:   

<table><tr><td colspan="1" rowspan="1">Cross-reactant</td><td colspan="1" rowspan="1">Target Concentration(ng/mL)</td><td colspan="1" rowspan="1">% Cross Reactivity</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">100 %</td></tr><tr><td colspan="1" rowspan="1">Cocaethylene</td><td colspan="1" rowspan="1">4,000</td><td colspan="1" rowspan="1">4.58 %</td></tr><tr><td colspan="1" rowspan="1">Cocaine (BS-480)</td><td colspan="1" rowspan="1">25,000</td><td colspan="1" rowspan="1">0.62%</td></tr><tr><td colspan="1" rowspan="1">Ecgonine</td><td colspan="1" rowspan="1">400,000</td><td colspan="1" rowspan="1">0.03 %</td></tr><tr><td colspan="1" rowspan="1">Ecgonine, Methyl Ester</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">0.00 %</td></tr><tr><td colspan="1" rowspan="1">Norcocaine</td><td colspan="1" rowspan="1">30,000</td><td colspan="1" rowspan="1">0.68 %</td></tr><tr><td colspan="1" rowspan="1">Atropine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">0.00 %</td></tr></table>

Structurally Unrelated Pharmacological Compounds   

<table><tr><td rowspan=1 colspan=1>Cross-reactant</td><td rowspan=1 colspan=1>Target Concentration(ng/mL)</td><td rowspan=1 colspan=1>% Cross Reactivity</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Amobarbital</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Amoxicillin</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Amphetamine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Bupropion</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Captopril</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Chlordiazepoxide</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Chlorpheniramine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Chlorpomazine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Dextromethorphan</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Digoxin</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Enalapril</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Fluoxetine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.01 %</td></tr><tr><td rowspan=1 colspan=1>Glyburide</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Lidocaine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Meperidine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Methadone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.01 %</td></tr><tr><td rowspan=1 colspan=1>Methamphetamine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Methaqualone</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Nicodine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Nifedipine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Phencyclidine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Phenobarbital</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Propoxyphene</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Ranitidine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Salicyluric acid</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Secobarbital</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>11-nor- THC-COOH</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Valproic Acid</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr><tr><td rowspan=1 colspan=1>Verapamil</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>0.00 %</td></tr></table>

4. Assay Reportable Range:

Not applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Two levels of calibrators (0 and $1 5 0 ~ \mathrm { n g / m L }$ are available for use with the Pointe Scientific Cocaine Metabolite Enzyme Immunoassay. A commercially available benzoylecgonine standard solution from Cerilliant Analytical Reference Standards is used that is traceable to NIST standard.

6. Detection Limit: Not applicable.

7. Assay Cut-Off:

The Pointe Scientific Cocaine Metabolite Enzyme Immunoassay has a cutoff of $1 5 0 ~ \mathrm { n g / m L }$ benzoylecgonine.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Two methods comparison studies were conducted, one on the BS-480 Chemistry Analyzer and one on the BS-800M Chemistry Analyzer. 114 unaltered clinical urine remnant samples were evaluated over 3 nonconsecutive days by the Pointe Scientific Cocaine Metabolite Enzyme Immunoassay and compared to LC/MS. Results. The data is summarized below for each analyzer.

# BS-480 Chemistry Analyzer:

<table><tr><td rowspan=1 colspan=1>CandidateDeviceResults</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>&lt; 75 ng/mLby LC/MS</td><td rowspan=1 colspan=1>75-150ng/mL byLC/MS</td><td rowspan=1 colspan=1>150-225ng/mL byLC/MS</td><td rowspan=1 colspan=1>&gt;225 ng/mLby LC/MS</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr></table>

# BA-800M Chemistry Analyzer:

<table><tr><td rowspan=1 colspan=1>CandidateDeviceResults</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>&lt; 75 ng/mLby LC/MS</td><td rowspan=1 colspan=1>75-150ng/mL byLC/MS</td><td rowspan=1 colspan=1>150-225ng/mL byLC/MS</td><td rowspan=1 colspan=1>&gt;225 ng/mLby LC/MS</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr></table>

Not applicable.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable.

# D Clinical Cut-Off:

# E Expected Values/Reference Range:

Not applicable.

# VII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# VIII Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.